China Renji Medical Group Limited (“China Renji” or the "Company", HKSE stockcode: 648) operates and manages a network of medical centres in China specialising in the diagnosis and treatment of tumour/cancer using PET-CT scans and specialized radiation therapy technologies.
Our goal is to build an extensive hospital and medical network in China. We are the first group to use Gamma system technologies in Shanghai. Currently, we manage and operate fourteen centres located in Shanghai, Beijing, Shenyang, Jinning, Shijiazhuang, Xian, Hefei, Wuhan, Shenzhen, Xinjiang and Zhengzhou. We are confident that our specialist experience and quality services, coupled with the expanding network of hospitals that we work with, will allow us to assist in the development of China’s medical industry.
Company Background
Our management
team possesses a wealth of knowledge in the Mainland’s healthcare
industry. We have created a novel business model that has enabled
hospitals to avoid the constraints of funding, budgetary difficulties,
and the problems associated with the lack of initial set up and
operational experience. Our profit-sharing leasing program permits
hospital to quickly benefit from our medical equipment, technical
expertise, and management experience, and by sharing a percentage
of their profits with us.
|
